Nastorazepide

Cat. No.:	HY-17617					
CAS No.:	209219-38-5					
Molecular Formula:	C ₂₉ H ₃₆ N ₄ O ₅					
Molecular Weight:	520.62					
Target:	Cholecystokinin Receptor					
Pathway:	GPCR/G Protein; Neuronal Signaling					
Storage:	Powder	-20°C	3 years			
		4°C	2 years			
	In solvent	-80°C	2 years			
		-20°C	1 year			

SOLVENT & SOLUBILITY

In Vitro DMSO * "≥" n Prepa Stock	DMSO:≥32 mg/mL (61.47 mM) * "≥" means soluble, but saturation unknown.						
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg		
		1 mM	1.9208 mL	9.6039 mL	19.2079 mL		
		5 mM	0.3842 mL	1.9208 mL	3.8416 mL		
		10 mM	0.1921 mL	0.9604 mL	1.9208 mL		
	Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.08 mg/mL (4.00 mM); Suspended solution; Need ultrasonic						
	 Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.00 mM); Clear solution 						

BIOLOGICAL ACTIVITY

DescriptionNastorazepide (Z-360) is a selective, orally available, 1,5-benzodiazepine-derivative gastrin/cholecystokinin 2 (CCK-2)
receptor antagonist with potential antineoplastic activity. Target⊠CCK-2in vitro: Z-360 binds to the gastrin/CCK-2 receptor,
thereby preventing receptor activation by gastrin, a peptide hormone frequently associated with the proliferation of
gastrointestinal and pancreatic tumor cells. Check for active clinical trials or closed clinical trials using this agent. in vivo: Z-
360 is a novel orally active CCK-2/gastrin receptor antagonist, significantly inhibits the growth of subcutaneous xenografts of
human pancreatic tumor cells in mice, and that Z-360 combined with gemcitabine prolonged survival in a pancreatic
carcinoma orthotopic xenograft mice.





REFERENCES

[1]. Kato H, et al. CCK-2/gastrin receptor signaling pathway is significant for gemcitabine-induced gene expression of VEGF in pancreatic carcinoma cells. Life Sci. 2011 Oct 24;89(17-18):603-8.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA